{"id":343802,"date":"2025-08-24T06:21:08","date_gmt":"2025-08-24T06:21:08","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/news-events\/data\/how-to-buy-apellis-pharmaceuticals\/"},"modified":"2025-08-24T06:21:08","modified_gmt":"2025-08-24T06:21:08","slug":"how-to-buy-apellis-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/","title":{"rendered":"How to buy Apellis Pharmaceuticals, Inc. (APLS) shares &#8211; Investment in Apellis Pharmaceuticals, Inc. (APLS) stock"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334081,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-343802","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"How to Buy Apellis Pharmaceuticals, Inc. (APLS) Shares - Investment in APellis Pharmaceuticals, Inc. (APLS) Stock","h1_source":{"label":"H1","type":"text","formatted_value":"How to Buy Apellis Pharmaceuticals, Inc. (APLS) Shares - Investment in APellis Pharmaceuticals, Inc. (APLS) Stock"},"description":"Learn how to buy Apellis Pharmaceuticals (APLS) shares with current price $27.97. Discover investment strategies, risks, and growth potential for this biotech leader.","description_source":{"label":"Description","type":"textarea","formatted_value":"Learn how to buy Apellis Pharmaceuticals (APLS) shares with current price $27.97. Discover investment strategies, risks, and growth potential for this biotech leader."},"intro":"Thinking about investing in a company that's revolutionizing eye disease treatment? Apellis Pharmaceuticals represents the exciting intersection of medical innovation and investment opportunity. With their groundbreaking SYFOVRE treatment for geographic atrophy and recent FDA approvals, this biotech firm offers both scientific promise and financial potential. Let's explore what makes APLS stock worth your attention.","intro_source":{"label":"Intro","type":"text","formatted_value":"Thinking about investing in a company that's revolutionizing eye disease treatment? Apellis Pharmaceuticals represents the exciting intersection of medical innovation and investment opportunity. With their groundbreaking SYFOVRE treatment for geographic atrophy and recent FDA approvals, this biotech firm offers both scientific promise and financial potential. Let's explore what makes APLS stock worth your attention."},"body_html":"<h2>Current Market Position and Entry Point<\/h2> <p>As of August 24, 2025, Apellis Pharmaceuticals (APLS) trades at <strong>$27.97<\/strong> per share. This price represents a crucial juncture for investors considering how to buy Apellis Pharmaceuticals, Inc. (APLS) shares, as the stock has shown remarkable recovery momentum in recent months.<\/p> <p><strong>Critical Date Alert<\/strong>: Mark <strong>November 4, 2025<\/strong> on your calendar. This is when Apellis releases their Q3 earnings report. Historical patterns show these events significantly impact APLS stock price movement.<\/p> <p><strong>Earnings Impact Analysis<\/strong>:<br\/> Looking at recent quarterly reports, Apellis stock typically experiences 5-15% price swings around earnings announcements. The Q2 2025 report on July 31st showed mixed results - revenue missed expectations but earnings per share beat estimates by 25%. This pattern suggests careful analysis of both top-line and bottom-line performance is essential when considering investment in Apellis Pharmaceuticals, Inc. (APLS) stock.<\/p> [cta_green text=\"Start trading\"]<h2>Six-Month Price Journey: From Struggle to Strength<\/h2> <p>Apellis shares have navigated a dramatic transformation over the past six months:<\/p> <ul> <li><strong>January 2025<\/strong>: Started at approximately $35.57, then began a concerning decline<\/li> <li><strong>February-March<\/strong>: Continued downward pressure, dropping to the $26-30 range<\/li> <li><strong>April-May<\/strong>: Reached concerning lows around $16-17, testing investor patience<\/li> <li><strong>June-July<\/strong>: Remarkable turnaround with +2.24% and +12.48% monthly gains respectively<\/li> <li><strong>August 2025<\/strong>: Continued recovery, reaching current levels around $28<\/li> <\/ul> <p>This represents a classic biotech volatility pattern - sharp declines followed by explosive recoveries. For those learning how to buy Apellis Pharmaceuticals, Inc. (APLS) shares, this history demonstrates both the risks and opportunities in pharmaceutical investing.<\/p> <h2>Price Forecast: 2025-2030 Outlook<\/h2> <p>Based on current analyst consensus and company developments, here's what to expect:<\/p> <ul> <li><strong>2025 Year-End<\/strong>: $30-34 range (moderate growth from current levels)<\/li> <li><strong>2026 Projection<\/strong>: $28-32 (consolidation phase expected)<\/li> <li><strong>2028 Outlook<\/strong>: $48-52 (significant growth potential from pipeline expansion)<\/li> <li><strong>2030 Vision<\/strong>: $50-55+ (long-term value creation from market leadership)<\/li> <\/ul> <p><strong>Verdict<\/strong>: <strong>BUY<\/strong> for long-term investors. The recent FDA approval for EMPAVELI and strong SYFOVRE performance create fundamental strength that supports future growth.<\/p> <h2>Risk Assessment vs. Positive Signals<\/h2> <h3>\u26a0\ufe0f Key Risks to Consider:<\/h3> <ul> <li><strong>Regulatory uncertainty<\/strong>: FDA decisions can make or break biotech stocks<\/li> <li><strong>Competition intensifying<\/strong>: Other companies developing similar treatments<\/li> <li><strong>Cash burn concerns<\/strong>: Despite $370M cash position, R&D costs remain high<\/li> <li><strong>Market volatility<\/strong>: Biotech stocks typically show higher beta than market average<\/li> <\/ul> <h3>\u2705 Positive Signals for 2025:<\/h3> <ul> <li><strong>FDA approval success<\/strong>: EMPAVELI approved for C3G\/IC-MPGN (<a href=\"https:\/\/www.globenewswire.com\/news-release\/2025\/07\/31\/3124861\/0\/en\/Apellis-Pharmaceuticals-Reports-Second-Quarter-2025-Financial-Results.html\">Q2 Earnings Report<\/a>)<\/li> <li><strong>Revenue growth<\/strong>: SYFOVRE delivered $151M in Q2 revenue, up 6% quarterly<\/li> <li><strong>Strategic partnerships<\/strong>: $300M royalty deal with Sobi provides financial stability<\/li> <li><strong>Market leadership<\/strong>: SYFOVRE captures &gt;60% new patient share in geographic atrophy<\/li> <\/ul> <h2>Recent News Impact Analysis<\/h2> <p>Apellis has been making waves in 2025 with several significant developments:<\/p> <ul> <li><strong>Q2 Earnings Performance<\/strong>: While revenue of $178M missed expectations, the EPS beat by 25% shows improving operational efficiency (<a href=\"https:\/\/www.ainvest.com\/news\/apellis-pharmaceuticals-reports-q2-revenue-expectations-celebrates-fda-approval-empaveli-2508\/\">AInvest Analysis<\/a>)<\/li> <li><strong>FDA Expansion<\/strong>: The approval of EMPAVELI for additional conditions opens a potential $500M per patient market opportunity (<a href=\"https:\/\/www.ainvest.com\/news\/apellis-pharmaceuticals-q2-2025-unraveling-contradictions-sales-dynamics-market-position-competitive-landscape-2508\/\">Market Analysis<\/a>)<\/li> <li><strong>Institutional Confidence<\/strong>: Fox Run Management's new investment in August 2025 signals continued professional interest (<a href=\"https:\/\/www.marketbeat.com\/instant-alerts\/filing-fox-run-management-llc-makes-new-investment-in-apellis-pharmaceuticals-inc-apls-2025-08-20\/\">Institutional Filing<\/a>)<\/li> <\/ul> <h2>Step-by-Step: How to Buy Apellis Pharmaceuticals, Inc. (APLS) Shares<\/h2> <table> <thead> <tr><th>Step<\/th><th>Action<\/th><th>Why It Matters<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Choose a trading platform<\/td><td>Ensure it offers NASDAQ access for US stocks<\/td><\/tr> <tr><td>2<\/td><td>Complete account verification<\/td><td>Most platforms require ID and address confirmation<\/td><\/tr> <tr><td>3<\/td><td>Deposit funds<\/td><td>Start with an amount you're comfortable risking<\/td><\/tr> <tr><td>4<\/td><td>Research current APLS price<\/td><td>Check real-time quotes before ordering<\/td><\/tr> <tr><td>5<\/td><td>Place your order<\/td><td>Use limit orders to control entry price<\/td><\/tr> <tr><td>6<\/td><td>Monitor your investment<\/td><td>Set price alerts for important levels<\/td><\/tr> <tr><td>7<\/td><td>Consider dollar-cost averaging<\/td><td>Spread purchases over time to reduce timing risk<\/td><\/tr> <\/tbody> <\/table> <h2>Smart Strategy for Beginners<\/h2> <p>For those new to how to buy Apellis Pharmaceuticals, Inc. (APLS) shares, here's my professional advice:<\/p> <ul> <li><strong>Start small<\/strong> - Biotech stocks can be volatile; begin with a position size that won't keep you up at night<\/li> <li><strong>Focus on long-term<\/strong> - Pharmaceutical development takes years; think in terms of 3-5 year horizons<\/li> <li><strong>Diversify appropriately<\/strong> - Don't put all your eggs in one biotech basket<\/li> <li><strong>Set stop-losses<\/strong> - Protect your capital from unexpected downturns<\/li> <\/ul> <p>And my humorous take: \"Trading APLS is like watching medical research - sometimes you need strong stomach for the clinical trials, but the successful treatments make it worth the wait!\"<\/p> <h2>Why Pocket Option Fits New Investors<\/h2> <p>For those considering how to buy Apellis Pharmaceuticals, Inc. (APLS) shares, Pocket Option offers several advantages:<\/p> <ul> <li><strong>Minimum deposit just $5<\/strong> - Perfect for testing strategies with minimal risk<\/li> <li><strong>Rapid verification<\/strong> - Start trading quickly with simple document upload<\/li> <li><strong>Multiple withdrawal options<\/strong> - Access your profits through various convenient methods<\/li> <li><strong>User-friendly platform<\/strong> - Designed for beginners while offering advanced features<\/li> <\/ul> <h2>Company Overview: Apellis in 2025<\/h2> <p>Apellis Pharmaceuticals stands as a global leader in complement-mediated disease treatment. The company has transitioned from clinical-stage to commercial-stage success with two approved therapies targeting serious conditions.<\/p> <p>Their flagship product SYFOVRE treats geographic atrophy, while EMPAVELI addresses multiple rare diseases. With $370 million in cash and growing revenue streams, Apellis demonstrates both scientific innovation and business acumen.<\/p> <p><strong>Interesting Fact<\/strong>: In 2025, Apellis achieved something rare in biotech - they successfully expanded their existing drug EMPAVELI to treat completely new conditions (C3G and IC-MPGN), effectively creating new revenue streams without developing entirely new compounds from scratch!<\/p> <p>For more educational content on trading strategies and market analysis, visit our <a href=\"\/blog\">Pocket Option blog<\/a> for regular updates and insights.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>Current Market Position and Entry Point<\/h2>\n<p>As of August 24, 2025, Apellis Pharmaceuticals (APLS) trades at <strong>$27.97<\/strong> per share. This price represents a crucial juncture for investors considering how to buy Apellis Pharmaceuticals, Inc. (APLS) shares, as the stock has shown remarkable recovery momentum in recent months.<\/p>\n<p><strong>Critical Date Alert<\/strong>: Mark <strong>November 4, 2025<\/strong> on your calendar. This is when Apellis releases their Q3 earnings report. Historical patterns show these events significantly impact APLS stock price movement.<\/p>\n<p><strong>Earnings Impact Analysis<\/strong>:<br \/> Looking at recent quarterly reports, Apellis stock typically experiences 5-15% price swings around earnings announcements. The Q2 2025 report on July 31st showed mixed results &#8211; revenue missed expectations but earnings per share beat estimates by 25%. This pattern suggests careful analysis of both top-line and bottom-line performance is essential when considering investment in Apellis Pharmaceuticals, Inc. (APLS) stock.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/en\/register\/\" class=\"po-cta-green\">Start trading\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>Six-Month Price Journey: From Struggle to Strength<\/h2>\n<p>Apellis shares have navigated a dramatic transformation over the past six months:<\/p>\n<ul>\n<li><strong>January 2025<\/strong>: Started at approximately $35.57, then began a concerning decline<\/li>\n<li><strong>February-March<\/strong>: Continued downward pressure, dropping to the $26-30 range<\/li>\n<li><strong>April-May<\/strong>: Reached concerning lows around $16-17, testing investor patience<\/li>\n<li><strong>June-July<\/strong>: Remarkable turnaround with +2.24% and +12.48% monthly gains respectively<\/li>\n<li><strong>August 2025<\/strong>: Continued recovery, reaching current levels around $28<\/li>\n<\/ul>\n<p>This represents a classic biotech volatility pattern &#8211; sharp declines followed by explosive recoveries. For those learning how to buy Apellis Pharmaceuticals, Inc. (APLS) shares, this history demonstrates both the risks and opportunities in pharmaceutical investing.<\/p>\n<h2>Price Forecast: 2025-2030 Outlook<\/h2>\n<p>Based on current analyst consensus and company developments, here&#8217;s what to expect:<\/p>\n<ul>\n<li><strong>2025 Year-End<\/strong>: $30-34 range (moderate growth from current levels)<\/li>\n<li><strong>2026 Projection<\/strong>: $28-32 (consolidation phase expected)<\/li>\n<li><strong>2028 Outlook<\/strong>: $48-52 (significant growth potential from pipeline expansion)<\/li>\n<li><strong>2030 Vision<\/strong>: $50-55+ (long-term value creation from market leadership)<\/li>\n<\/ul>\n<p><strong>Verdict<\/strong>: <strong>BUY<\/strong> for long-term investors. The recent FDA approval for EMPAVELI and strong SYFOVRE performance create fundamental strength that supports future growth.<\/p>\n<h2>Risk Assessment vs. Positive Signals<\/h2>\n<h3>\u26a0\ufe0f Key Risks to Consider:<\/h3>\n<ul>\n<li><strong>Regulatory uncertainty<\/strong>: FDA decisions can make or break biotech stocks<\/li>\n<li><strong>Competition intensifying<\/strong>: Other companies developing similar treatments<\/li>\n<li><strong>Cash burn concerns<\/strong>: Despite $370M cash position, R&#038;D costs remain high<\/li>\n<li><strong>Market volatility<\/strong>: Biotech stocks typically show higher beta than market average<\/li>\n<\/ul>\n<h3>\u2705 Positive Signals for 2025:<\/h3>\n<ul>\n<li><strong>FDA approval success<\/strong>: EMPAVELI approved for C3G\/IC-MPGN (<a href=\"https:\/\/www.globenewswire.com\/news-release\/2025\/07\/31\/3124861\/0\/en\/Apellis-Pharmaceuticals-Reports-Second-Quarter-2025-Financial-Results.html\">Q2 Earnings Report<\/a>)<\/li>\n<li><strong>Revenue growth<\/strong>: SYFOVRE delivered $151M in Q2 revenue, up 6% quarterly<\/li>\n<li><strong>Strategic partnerships<\/strong>: $300M royalty deal with Sobi provides financial stability<\/li>\n<li><strong>Market leadership<\/strong>: SYFOVRE captures &gt;60% new patient share in geographic atrophy<\/li>\n<\/ul>\n<h2>Recent News Impact Analysis<\/h2>\n<p>Apellis has been making waves in 2025 with several significant developments:<\/p>\n<ul>\n<li><strong>Q2 Earnings Performance<\/strong>: While revenue of $178M missed expectations, the EPS beat by 25% shows improving operational efficiency (<a href=\"https:\/\/www.ainvest.com\/news\/apellis-pharmaceuticals-reports-q2-revenue-expectations-celebrates-fda-approval-empaveli-2508\/\">AInvest Analysis<\/a>)<\/li>\n<li><strong>FDA Expansion<\/strong>: The approval of EMPAVELI for additional conditions opens a potential $500M per patient market opportunity (<a href=\"https:\/\/www.ainvest.com\/news\/apellis-pharmaceuticals-q2-2025-unraveling-contradictions-sales-dynamics-market-position-competitive-landscape-2508\/\">Market Analysis<\/a>)<\/li>\n<li><strong>Institutional Confidence<\/strong>: Fox Run Management&#8217;s new investment in August 2025 signals continued professional interest (<a href=\"https:\/\/www.marketbeat.com\/instant-alerts\/filing-fox-run-management-llc-makes-new-investment-in-apellis-pharmaceuticals-inc-apls-2025-08-20\/\">Institutional Filing<\/a>)<\/li>\n<\/ul>\n<h2>Step-by-Step: How to Buy Apellis Pharmaceuticals, Inc. (APLS) Shares<\/h2>\n<table>\n<thead>\n<tr>\n<th>Step<\/th>\n<th>Action<\/th>\n<th>Why It Matters<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Choose a trading platform<\/td>\n<td>Ensure it offers NASDAQ access for US stocks<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Complete account verification<\/td>\n<td>Most platforms require ID and address confirmation<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>Deposit funds<\/td>\n<td>Start with an amount you&#8217;re comfortable risking<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Research current APLS price<\/td>\n<td>Check real-time quotes before ordering<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Place your order<\/td>\n<td>Use limit orders to control entry price<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Monitor your investment<\/td>\n<td>Set price alerts for important levels<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>Consider dollar-cost averaging<\/td>\n<td>Spread purchases over time to reduce timing risk<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>Smart Strategy for Beginners<\/h2>\n<p>For those new to how to buy Apellis Pharmaceuticals, Inc. (APLS) shares, here&#8217;s my professional advice:<\/p>\n<ul>\n<li><strong>Start small<\/strong> &#8211; Biotech stocks can be volatile; begin with a position size that won&#8217;t keep you up at night<\/li>\n<li><strong>Focus on long-term<\/strong> &#8211; Pharmaceutical development takes years; think in terms of 3-5 year horizons<\/li>\n<li><strong>Diversify appropriately<\/strong> &#8211; Don&#8217;t put all your eggs in one biotech basket<\/li>\n<li><strong>Set stop-losses<\/strong> &#8211; Protect your capital from unexpected downturns<\/li>\n<\/ul>\n<p>And my humorous take: &#8220;Trading APLS is like watching medical research &#8211; sometimes you need strong stomach for the clinical trials, but the successful treatments make it worth the wait!&#8221;<\/p>\n<h2>Why Pocket Option Fits New Investors<\/h2>\n<p>For those considering how to buy Apellis Pharmaceuticals, Inc. (APLS) shares, Pocket Option offers several advantages:<\/p>\n<ul>\n<li><strong>Minimum deposit just $5<\/strong> &#8211; Perfect for testing strategies with minimal risk<\/li>\n<li><strong>Rapid verification<\/strong> &#8211; Start trading quickly with simple document upload<\/li>\n<li><strong>Multiple withdrawal options<\/strong> &#8211; Access your profits through various convenient methods<\/li>\n<li><strong>User-friendly platform<\/strong> &#8211; Designed for beginners while offering advanced features<\/li>\n<\/ul>\n<h2>Company Overview: Apellis in 2025<\/h2>\n<p>Apellis Pharmaceuticals stands as a global leader in complement-mediated disease treatment. The company has transitioned from clinical-stage to commercial-stage success with two approved therapies targeting serious conditions.<\/p>\n<p>Their flagship product SYFOVRE treats geographic atrophy, while EMPAVELI addresses multiple rare diseases. With $370 million in cash and growing revenue streams, Apellis demonstrates both scientific innovation and business acumen.<\/p>\n<p><strong>Interesting Fact<\/strong>: In 2025, Apellis achieved something rare in biotech &#8211; they successfully expanded their existing drug EMPAVELI to treat completely new conditions (C3G and IC-MPGN), effectively creating new revenue streams without developing entirely new compounds from scratch!<\/p>\n<p>For more educational content on trading strategies and market analysis, visit our <a href=\"\/blog\">Pocket Option blog<\/a> for regular updates and insights.<\/p>\n"},"faq":[{"question":"What is Apellis Pharmaceuticals' main business?","answer":"Apellis develops and commercializes therapies for complement-mediated diseases, with focus on innovative C3-targeting treatments."},{"question":"How often does APLS stock pay dividends?","answer":"Apellis does not currently pay dividends as they reinvest profits into research and development."},{"question":"What was Apellis' revenue in their last quarter?","answer":"Q2 2025 revenue was $178 million, with $171 million from U.S. product sales."},{"question":"Is APLS stock considered high-risk?","answer":"Yes, as a clinical-stage biopharmaceutical company, APLS carries higher risk than established pharmaceutical stocks."},{"question":"Where can I find Apellis' latest financial reports?","answer":"All official reports are available on their investor relations website and SEC filings."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"What is Apellis Pharmaceuticals' main business?","answer":"Apellis develops and commercializes therapies for complement-mediated diseases, with focus on innovative C3-targeting treatments."},{"question":"How often does APLS stock pay dividends?","answer":"Apellis does not currently pay dividends as they reinvest profits into research and development."},{"question":"What was Apellis' revenue in their last quarter?","answer":"Q2 2025 revenue was $178 million, with $171 million from U.S. product sales."},{"question":"Is APLS stock considered high-risk?","answer":"Yes, as a clinical-stage biopharmaceutical company, APLS carries higher risk than established pharmaceutical stocks."},{"question":"Where can I find Apellis' latest financial reports?","answer":"All official reports are available on their investor relations website and SEC filings."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>How to buy Apellis Pharmaceuticals, Inc. (APLS) shares - Investment in Apellis Pharmaceuticals, Inc. (APLS) stock<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"How to buy Apellis Pharmaceuticals, Inc. (APLS) shares - Investment in Apellis Pharmaceuticals, Inc. (APLS) stock\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-24T06:21:08+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"How to buy Apellis Pharmaceuticals, Inc. (APLS) shares &#8211; Investment in Apellis Pharmaceuticals, Inc. (APLS) stock\",\"datePublished\":\"2025-08-24T06:21:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/\"},\"wordCount\":17,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/\",\"name\":\"How to buy Apellis Pharmaceuticals, Inc. (APLS) shares - Investment in Apellis Pharmaceuticals, Inc. (APLS) stock\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp\",\"datePublished\":\"2025-08-24T06:21:08+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"How to buy Apellis Pharmaceuticals, Inc. (APLS) shares &#8211; Investment in Apellis Pharmaceuticals, Inc. (APLS) stock\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/en\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/en\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"How to buy Apellis Pharmaceuticals, Inc. (APLS) shares - Investment in Apellis Pharmaceuticals, Inc. (APLS) stock","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/","og_locale":"en_US","og_type":"article","og_title":"How to buy Apellis Pharmaceuticals, Inc. (APLS) shares - Investment in Apellis Pharmaceuticals, Inc. (APLS) stock","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-24T06:21:08+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"How to buy Apellis Pharmaceuticals, Inc. (APLS) shares &#8211; Investment in Apellis Pharmaceuticals, Inc. (APLS) stock","datePublished":"2025-08-24T06:21:08+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/"},"wordCount":17,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/","url":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/","name":"How to buy Apellis Pharmaceuticals, Inc. (APLS) shares - Investment in Apellis Pharmaceuticals, Inc. (APLS) stock","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp","datePublished":"2025-08-24T06:21:08+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals11.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/en\/"},{"@type":"ListItem","position":2,"name":"How to buy Apellis Pharmaceuticals, Inc. (APLS) shares &#8211; Investment in Apellis Pharmaceuticals, Inc. (APLS) stock"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/en\/#website","url":"https:\/\/pocketoption.com\/blog\/en\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/en\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":343833,"slug":"how-to-buy-apellis-pharmaceuticals","post_title":"Comment acheter des actions Apellis Pharmaceuticals, Inc. (APLS) - Investir dans les actions Apellis Pharmaceuticals, Inc. (APLS)","href":"https:\/\/pocketoption.com\/blog\/fr\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/"},"it_IT":{"locale":"it_IT","id":343834,"slug":"how-to-buy-apellis-pharmaceuticals","post_title":"Come acquistare azioni Apellis Pharmaceuticals, Inc. (APLS) - Investire in azioni Apellis Pharmaceuticals, Inc. (APLS)","href":"https:\/\/pocketoption.com\/blog\/it\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/"},"pl_PL":{"locale":"pl_PL","id":343832,"slug":"how-to-buy-apellis-pharmaceuticals","post_title":"Jak kupi\u0107 akcje Apellis Pharmaceuticals, Inc. (APLS) - Inwestycja w akcje Apellis Pharmaceuticals, Inc. (APLS)","href":"https:\/\/pocketoption.com\/blog\/pl\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/"},"es_ES":{"locale":"es_ES","id":343828,"slug":"how-to-buy-apellis-pharmaceuticals","post_title":"C\u00f3mo comprar acciones de Apellis Pharmaceuticals, Inc. (APLS) - Inversi\u00f3n en acciones de Apellis Pharmaceuticals, Inc. (APLS)","href":"https:\/\/pocketoption.com\/blog\/es\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/"},"th_TH":{"locale":"th_TH","id":343829,"slug":"how-to-buy-apellis-pharmaceuticals","post_title":"\u0e27\u0e34\u0e18\u0e35\u0e0b\u0e37\u0e49\u0e2d\u0e2b\u0e38\u0e49\u0e19 Apellis Pharmaceuticals, Inc. (APLS) - \u0e01\u0e32\u0e23\u0e25\u0e07\u0e17\u0e38\u0e19\u0e43\u0e19\u0e2b\u0e38\u0e49\u0e19 Apellis Pharmaceuticals, Inc. (APLS)","href":"https:\/\/pocketoption.com\/blog\/th\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/"},"tr_TR":{"locale":"tr_TR","id":343830,"slug":"how-to-buy-apellis-pharmaceuticals","post_title":"Apellis Pharmaceuticals, Inc. (APLS) Hisseleri Nas\u0131l Al\u0131n\u0131r - Apellis Pharmaceuticals, Inc. (APLS) Hisse Senedi Yat\u0131r\u0131m\u0131","href":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/"},"vt_VT":{"locale":"vt_VT","id":343831,"slug":"how-to-buy-apellis-pharmaceuticals","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Apellis Pharmaceuticals, Inc. (APLS) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Apellis Pharmaceuticals, Inc. (APLS)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/"},"pt_AA":{"locale":"pt_AA","id":343827,"slug":"how-to-buy-apellis-pharmaceuticals","post_title":"Como comprar a\u00e7\u00f5es da Apellis Pharmaceuticals, Inc. (APLS) - Investimento em a\u00e7\u00f5es da Apellis Pharmaceuticals, Inc. (APLS)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-apellis-pharmaceuticals\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts\/343802","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/comments?post=343802"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts\/343802\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/media\/334081"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/media?parent=343802"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/categories?post=343802"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/tags?post=343802"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}